Clinical Trial: A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07750353) titled 'A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas' on Aug. 02.

Brief Summary: This is a non-randomized, open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of sacituzumab tirumotecan (hereafter referred to as sac-TMT) in patients with unresectable thymic carcinoma who have a history of platinum-based combination chemotherapy.

Study Start Date: Feb. 01, 2027

Study Type: INTERVENTIONAL

Condition: Unresectable Thymic Carcinoma

Intervention: DRUG: Sacituzumab Tirumotecan (Sac-TMT)

Sacituzumab tiru...